Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.47 |
| ▸ | ITGAL | P20701 | 3/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.41 |
| ▸ | CALCR | P30988 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774663 | 1.00 | SLC15A2 (0.52) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL1161012 | 0.86 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL1229751 | 0.86 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL308989 | 0.86 | ITGB2 (0.59) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL27469252 | 0.85 | ITGB2 (0.58) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL30538870 | 0.82 | SLC15A2 (0.43) | SLC15A2RENRAMP3CALCRBACE1 | |
| SCHEMBL30538867 | 0.82 | SLC15A2 (0.43) | SLC15A2RENRAMP3CALCRBACE1 | |
| SCHEMBL30656637 | 0.82 | ITGB2 (0.53) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL29368268 | 0.82 | SLC15A2 (0.53) | SLC15A2ITGB2ICAM1ITGALSLC6A5 | |
| SCHEMBL18381336 | 0.82 | ITGB2 (0.55) | SLC15A2ITGB2ICAM1ITGALSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777875-B1 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250215066-A1 | HYDROGEL-FORMING PROTEINS | ZHAW ZÜRCHER HOCHSCHULE FÜR ANGEWANDTE WISSENSCHAFTEN (CH) | 2025-07-03 | — | — | US | disclosed |
| US-12006085-B2 | Fill-finish process for peptide solutions | 3-D MATRIX, LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| US-11839694-B2 | Compositions and methods for promoting hemostasis and other physiological activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4286397-A1 | HYDROGEL-FORMING PROTEINS | ETH Zurich (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3-D MATRIX, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2283851-B1 | Compositions for promoting hemostasis | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220324601-A1 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4049671-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220258900-A9 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4023240-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | IAPP, NGLY1, VIP | SLC15A2 2391/4885ITGB2 2631/4885ICAM1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.